| Randomized phase II clinical trial of cisplatin/carboplatin and etoposide (CE) alone or in combination with nivolumab as frontline therapy for extensive-stage small cell lung … T Leal, Y Wang, A Dowlati, DQA Lewis, Y Chen, AR Mohindra, M Razaq, ... Journal of Clinical Oncology 38 (15_suppl), 9000-9000, 2020 | 118 | 2020 |
| ECOG-ACRIN 5162: A phase II study of osimertinib 160 mg in NSCLC with EGFR exon 20 insertions. Z Piotrowska, Y Wang, LV Sequist, SS Ramalingam Journal of Clinical Oncology 38 (15_suppl), 9513-9513, 2020 | 106 | 2020 |
| Use of Fluoro-[18F]-Deoxy-2-D-Glucose Positron Emission Tomography/Computed Tomography to Predict Immunotherapy Treatment Response in Patients With Squamous Cell Oral Cavity … H Shah, Y Wang, SC Cheng, L Gunasti, YH Chen, A Lako, J Guenette, ... JAMA Otolaryngology–Head & Neck Surgery 148 (3), 268-276, 2022 | 4 | 2022 |
| Bevacizumab’s Association With a Decreased Risk of Brain Metastases in ECOG-ACRIN E1505, a Phase 3 Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab in … JM Varlotto, Y Wang, Z Sun, HA Wakelee, S Ramalingam, J Schiller JTO Clinical and Research Reports 3 (3), 100274, 2022 | 3 | 2022 |
| Correlation of 68Ga-DOTATATE uptake on PET/CT with pathologic features of cellular proliferation in neuroendocrine neoplasms S Karls, R Gold, S Kravets, Y Wang, SC Cheng, K Perez, J Chan, ... Annals of Nuclear Medicine 35 (9), 1066-1077, 2021 | 3 | 2021 |
